摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-phenyl-N-(pyridin-3-ylmethyl)quinazolin-4-amine

中文名称
——
中文别名
——
英文名称
2-phenyl-N-(pyridin-3-ylmethyl)quinazolin-4-amine
英文别名
——
2-phenyl-N-(pyridin-3-ylmethyl)quinazolin-4-amine化学式
CAS
——
化学式
C20H16N4
mdl
——
分子量
312.374
InChiKey
NWGXQMVEYOMULC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.3
  • 重原子数:
    24
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.05
  • 拓扑面积:
    50.7
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

  • 作为产物:
    描述:
    参考文献:
    名称:
    喹唑啉衍生物作为有效抗克鲁氏锥虫药物的合成,2D-QSAR研究和生物学评价
    摘要:
    背景:恰加斯病感染了全世界约700万人。目前只有两种药物可用于治疗这种寄生虫病,即苯并尼达唑(Bzn)和硝呋替莫(Nfx)。两种药物在该疾病的慢性期均具有有限的疗效。因此,持续的研究是迫切需要以发现新颖的治疗选择。 目的:开发更安全,更有效的治疗性抗-T。Cruzi药物仍然是锥虫杀伤性化疗的主要目标。 方法:研究了一组喹唑啉酮和喹唑啉衍生物作为锥虫杀螨剂的合成,2D-QSAR和类药物理化性质。体外针对克氏锥虫(图拉胡恩(Tulahuen)菌株,Tul 2原种)的表鞭毛纲动物和血流类锥鞭毛纲动物筛选了所有化合物。 结果:在合成和测试的34种化合物中,有6种化合物(5a,5b,9b,9h,13f和13p)对前鞭毛体和三鞭毛体均显示出显着活性,而对Vero细胞无毒性。 结论:这些喹唑啉酮和喹唑啉衍生物的抗原生动物活性代表了针对旨在开发查加斯病的新型化学疗法的药物化学程序的有趣起点。
    DOI:
    10.2174/1573406414666181005145042
点击查看最新优质反应信息

文献信息

  • Quinazoline derivatives as medicaments
    申请人:Chakravarty Sarvajit
    公开号:US20050171123A1
    公开(公告)日:2005-08-04
    The invention is directed to methods to inhibit TGF-β and/or p38-α kinase using compounds of the formula or the pharmaceutically acceptable salts thereof wherein R 3 is a noninterfering substituent; each Z is CR 2 or N, wherein no more than two Z positions in ring A are N, and wherein two adjacent Z positions in ring A cannot be N; each R 2 is independently a noninterfering substituent; L is a linker; n is 0 or 1; and Ar′ is the residue of a cyclic aliphatic, cyclic heteroaliphatic, aromatic or heteroaromatic moiety optionally substituted with 1-3 noninterfering substituents.
    该发明涉及使用以下化合物或其药学可接受的盐来抑制TGF-β和/或p38-α激酶的方法,其中R3是非干扰性取代基;每个Z是CR2或N,在环A中不超过两个Z位置是N,并且环A中两个相邻的Z位置不能是N;每个R2是独立的非干扰性取代基;L是连接基;n为0或1;Ar'是一个环状脂肪族、环状杂脂族、芳香族或杂芳香族残基,可选地取代1-3个非干扰性取代基。
  • Hyperglycosylated variants of interferon alfacon-1
    申请人:Alios Biopharma Inc.
    公开号:EP2093235A1
    公开(公告)日:2009-08-26
    The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites. The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or nonnative glycosylation sites, as well as erythropoietin and darbepoetin alfa, each of which are linked to a penetrating peptide that facilitates translocation of a substance across a biological barrier as well as pharmaceutical compositions, including oral formulations, of the same. The present invention further provides oral formulations of hyperglycosylated or protease-resistant, hyperglycosylated polypeptide variants, which polypeptide variants lack at least one protease cleavage site found in a parent polypeptide, and thus exhibit increased protease resistance compared to the parent polypeptide, which polypeptide variants further include (1) a carbohydrate moiety covalently linked to at least one non-native glycosylation site not found in the parent protein therapeutic or (2) a carbohydrate moiety covalently linked to at least one native glycosylation site found but not glycosylated in the parent protein therapeutic. The present invention further provides compositions, including oral pharmaceutical compositions, comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides containers, devices, and kits comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides therapeutic methods involving administering an effective amount of an oral pharmaceutical composition comprising a synthetic Type I interferon receptor polypeptide agonist, a hyperglycosylated polypeptide variant, or a hyperglycosylated, protease-resistant polypeptide variant to an individual in need thereof.
    本发明提供合成的I型干扰素受体多肽激动剂,包括共识或混合I型干扰素受体多肽激动剂,含有一个或多个原生或非原生糖基化位点。本发明提供合成的 I 型干扰素受体多肽激动剂,包括共识或混合 I 型干扰素受体多肽激动剂,含有一个或多个原生或非原生糖基化位点,以及促红细胞生成素和达贝胎素α,其中每一种都与促进物质通过生物屏障转运的穿透肽相连,以及药物组合物,包括其口服制剂。本发明进一步提供了高糖基化或抗蛋白酶的高糖基化多肽变体的口服制剂,这些多肽变体缺乏母体多肽中的至少一个蛋白酶裂解位点,因此与母体多肽相比表现出更强的抗蛋白酶能力、多肽变体进一步包括(1)与至少一个非原生糖基化位点共价连接的碳水化合物分子,该糖基化位点在母体蛋白治疗剂中未发现;或(2)与至少一个原生糖基化位点共价连接的碳水化合物分子,该糖基化位点在母体蛋白治疗剂中发现但未糖基化。本发明进一步提供了包含合成的 I 型干扰素受体多肽激动剂、高糖基化多肽变体或高糖基化、抗蛋白酶多肽变体的组合物,包括口服药物组合物。本发明进一步提供了包含合成 I 型干扰素受体多肽激动剂、高糖基化多肽变体或高糖基化、抗蛋白酶多肽变体的容器、装置和试剂盒。本发明进一步提供了治疗方法,包括向有需要的个体施用有效量的口服药物组合物,该组合物包含合成的I型干扰素受体多肽激动剂、高糖基化多肽变体或高糖基化、抗蛋白酶多肽变体。
  • Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
    申请人:Hong Jin
    公开号:US20060182716A1
    公开(公告)日:2006-08-17
    The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites. The present invention further provides oral formulations of protease-resistant or protease-resistant, hyperglycosylated polypeptide variants, which polypeptide variants lack at least one protease cleavage site found in a parent polypeptide, and thus exhibit increased protease resistance compared to the parent polypeptide, which polypeptide variants further include (1) a carbohydrate moiety covalently linked to at least one non-native glycosylation site not found in the parent protein therapeutic or (2) a carbohydrate moiety covalently linked to at least one native glycosylation site found but not glycosylated in the parent protein therapeutic. The present invention further provides compositions, including oral pharmaceutical compositions, comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, the protease-resistant polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides containers, devices, and kits comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, the protease-resistant polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides therapeutic methods involving administering an effective amount of an oral pharmaceutical composition comprising a synthetic Type I interferon receptor polypeptide agonist, a hyperglycosylated polypeptide variant, a protease-resistant polypeptide variant, or a hyperglycosylated, protease-resistant polypeptide variant to an individual in need thereof.
    本发明提供合成的I型干扰素受体多肽激动剂,包括共识或混合I型干扰素受体多肽激动剂,含有一个或多个原生或非原生糖基化位点。本发明进一步提供了抗蛋白酶或抗蛋白酶、高糖基化多肽变体的口服制剂,这些多肽变体缺乏母体多肽中的至少一个蛋白酶裂解位点,因此与母体多肽相比,表现出更强的抗蛋白酶能力、多肽变体进一步包括(1)与至少一个非原生糖基化位点共价连接的碳水化合物分子,该糖基化位点在母体蛋白治疗剂中未发现;或(2)与至少一个原生糖基化位点共价连接的碳水化合物分子,该糖基化位点在母体蛋白治疗剂中发现但未糖基化。本发明进一步提供了包含合成的 I 型干扰素受体多肽激动剂、高糖基化多肽变体、抗蛋白酶多肽变体或高糖基化、抗蛋白酶多肽变体的组合物,包括口服药物组合物。本发明进一步提供了包含合成 I 型干扰素受体多肽激动剂、高糖基化多肽变体、抗蛋白酶多肽变体或高糖基化、抗蛋白酶多肽变体的容器、装置和试剂盒。本发明进一步提供了治疗方法,包括向有需要的个体施用有效量的口服药物组合物,该组合物包含合成的Ⅰ型干扰素受体多肽激动剂、高糖基化多肽变体、抗蛋白酶多肽变体或高糖基化、抗蛋白酶多肽变体。
  • Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same
    申请人:Blatt M. Lawrence
    公开号:US20060204473A1
    公开(公告)日:2006-09-14
    The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites. The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites, as well as erythropoietin and darbepoetin alfa, each of which are linked to a penetrating peptide that facilitates translocation of a substance across a biological barrier as well as pharmaceutical compositions, including oral formulations, of the same. The present invention further provides oral formulations of hyperglycosylated or protease-resistant, hyperglycosylated polypeptide variants, which polypeptide variants lack at least one protease cleavage site found in a parent polypeptide, and thus exhibit increased protease resistance compared to the parent polypeptide, which polypeptide variants further include (1) a carbohydrate moiety covalently linked to at least one non-native glycosylation site not found in the parent protein therapeutic or (2) a carbohydrate moiety covalently linked to at least one native glycosylation site found but not glycosylated in the parent protein therapeutic. The present invention further provides compositions, including oral pharmaceutical compositions, comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides containers, devices, and kits comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides therapeutic methods involving administering an effective amount of an oral pharmaceutical composition comprising a synthetic Type I interferon receptor polypeptide agonist, a hyperglycosylated polypeptide variant, or a hyperglycosylated, protease-resistant polypeptide variant to an individual in need thereof.
    本发明提供合成的I型干扰素受体多肽激动剂,包括共识的或混合的I型干扰素受体多肽激动剂,含有一个或多个原生或非原生糖基化位点。本发明提供合成的 I 型干扰素受体多肽激动剂,包括共识或混合 I 型干扰素受体多肽激动剂,含有一个或多个原生或非原生糖基化位点,以及促红细胞生成素和达贝胎素α,其中每一种都与促进物质通过生物屏障转运的穿透肽相连,以及药物组合物,包括其口服制剂。本发明进一步提供了高糖基化或抗蛋白酶的高糖基化多肽变体的口服制剂,这些多肽变体缺乏母体多肽中的至少一个蛋白酶裂解位点,因此与母体多肽相比表现出更强的抗蛋白酶能力、多肽变体进一步包括(1)与至少一个非原生糖基化位点共价连接的碳水化合物分子,该糖基化位点在母体蛋白治疗剂中未发现;或(2)与至少一个原生糖基化位点共价连接的碳水化合物分子,该糖基化位点在母体蛋白治疗剂中发现但未糖基化。本发明进一步提供了包含合成的 I 型干扰素受体多肽激动剂、高糖基化多肽变体或高糖基化、抗蛋白酶多肽变体的组合物,包括口服药物组合物。本发明进一步提供了包含合成 I 型干扰素受体多肽激动剂、高糖基化多肽变体或高糖基化、抗蛋白酶多肽变体的容器、装置和试剂盒。本发明进一步提供了治疗方法,包括向有需要的个体施用有效量的口服药物组合物,该组合物包含合成的I型干扰素受体多肽激动剂、高糖基化多肽变体或高糖基化、抗蛋白酶多肽变体。
  • Synthesis and SAR study of acridine, 2-methylquinoline and 2-phenylquinazoline analogues as anti-prion agents
    作者:H. Cope、R. Mutter、W. Heal、C. Pascoe、P. Brown、S. Pratt、B. Chen
    DOI:10.1016/j.ejmech.2006.05.002
    日期:2006.10
    Transmissible spongiform encephalopathies (TSEs) are thought to arise from aggregation of a protease resistant protein denoted PrPSc, which is a misfolded isoform of the normal cellular prion protein PrPC. Using virtual high-throughput screening we have selected structures analogous to acridine, 2-methyquinoline and 2-phenylquinazoline as potential therapeutic candidates for the treatment of TSEs. From the synthesis and screening of constructed libraries we have shown that an electron-rich aromatic ring attached through an amine linker to the position para to the ring nitrogen is beneficial to both binding to PrPC and the suppression of PrPSc accumulation for acridine and 2-methylquinoline analogues. 2-Phenylquinazoline analogues appear to utilise a different mode of action by binding at a different location and/or pose. We report IC(50)s in the nanomolar range. (c) 2006 Elsevier Masson SAS. All rights reserved.
查看更多